PRA Health Sciences (PRAH) Tops Q1 EPS by 4c, Offers FY Guidance

PRA Health Sciences (NASDAQ: PRAH) reported Q1 EPS of $1.10, $0.04 better than the analyst estimate of $1.06. Revenue for the quarter came in at $722 million versus the consensus estimate of $732.26 million.

GUIDANCE:

PRA Health Sciences sees FY2019 EPS of $4.93-$5.08, versus the consensus of $5.02. PRA Health Sciences sees FY2019 revenue of $3.09-3.2 billion, versus the consensus of $3.14 billion.

For earnings history and earnings-related data on PRA Health Sciences (PRAH) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c